Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST)

<strong>Objective</strong> Report results from PERSIST, a real-life, observational, prospective cohort study of CT-P13, an infliximab (IFX) biosimilar, for treatment of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) or psoriatic arthritis (PsA) who were biologic-naï...

詳細記述

書誌詳細
主要な著者: Taylor, PC, Christensen, R, Moosavi, S, Selema, P, Guilatco, R, Fowler, H, Mueller, M, Liau, KF, Haraoui, B
フォーマット: Journal article
言語:English
出版事項: British Society for Rheumatology 2021

類似資料